12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

The open-label, Australian pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte paclitaxel-eluting stent in in-stent late lumen loss at 9 months post-implantation (0.39 vs. 0.44 mm, p=0.0012 for non-inferiority). At 12...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >